These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28440912)

  • 21. Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations.
    Yang XR; Rotunno M; Xiao Y; Ingvar C; Helgadottir H; Pastorino L; van Doorn R; Bennett H; Graham C; Sampson JN; Malasky M; Vogt A; Zhu B; Bianchi-Scarra G; Bruno W; Queirolo P; Fornarini G; Hansson J; Tuominen R; Burdett L; Hicks B; Hutchinson A; Jones K; Yeager M; Chanock SJ; Landi MT; Höiom V; Olsson H; Gruis N; Ghiorzo P; Tucker MA; Goldstein AM
    Hum Genet; 2016 Nov; 135(11):1241-1249. PubMed ID: 27449771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.
    Ramsey MR; Krishnamurthy J; Pei XH; Torrice C; Lin W; Carrasco DR; Ligon KL; Xiong Y; Sharpless NE
    Cancer Res; 2007 May; 67(10):4732-41. PubMed ID: 17510401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A genetic variant in CDKN2A/B gene is associated with the increased risk of breast cancer.
    ShahidSales S; Mehramiz M; Ghasemi F; Aledavood A; Shamsi M; Hassanian SM; Ghayour-Mobarhan M; Avan A
    J Clin Lab Anal; 2018 Jan; 32(1):. PubMed ID: 28276595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Objective assessment of the evolutionary action equation for the fitness effect of missense mutations across CAGI-blinded contests.
    Katsonis P; Lichtarge O
    Hum Mutat; 2017 Sep; 38(9):1072-1084. PubMed ID: 28544059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1.
    Zhang S; Ramsay ES; Mock BA
    Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2429-34. PubMed ID: 9482902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crohn disease risk prediction-Best practices and pitfalls with exome data.
    Giollo M; Jones DT; Carraro M; Leonardi E; Ferrari C; Tosatto SCE
    Hum Mutat; 2017 Sep; 38(9):1193-1200. PubMed ID: 28087895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
    McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
    Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In silico analysis of structural and functional consequences in p16INK4A by deleterious nsSNPs associated CDKN2A gene in malignant melanoma.
    Rajasekaran R; Priya Doss CG; Sudandiradoss C; Ramanathan K; Sethumadhavan R
    Biochimie; 2008 Oct; 90(10):1523-9. PubMed ID: 18573309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conspirators in a capital crime: co-deletion of p18INK4c and p16INK4a/p14ARF/p15INK4b in glioblastoma multiforme.
    Solomon DA; Kim JS; Jean W; Waldman T
    Cancer Res; 2008 Nov; 68(21):8657-60. PubMed ID: 18974105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting pathogenicity of missense variants with weakly supervised regression.
    Cao Y; Sun Y; Karimi M; Chen H; Moronfoye O; Shen Y
    Hum Mutat; 2019 Sep; 40(9):1579-1592. PubMed ID: 31144781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced Megakaryopoiesis and Platelet Activity in Hypercholesterolemic, B6-Ldlr-/-, Cdkn2a-Deficient Mice.
    Wang W; Oh S; Koester M; Abramowicz S; Wang N; Tall AR; Welch CL
    Circ Cardiovasc Genet; 2016 Jun; 9(3):213-22. PubMed ID: 27098250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Critical assessment of variant prioritization methods for rare disease diagnosis within the rare genomes project.
    Stenton SL; O'Leary MC; Lemire G; VanNoy GE; DiTroia S; Ganesh VS; Groopman E; O'Heir E; Mangilog B; Osei-Owusu I; Pais LS; Serrano J; Singer-Berk M; Weisburd B; Wilson MW; Austin-Tse C; Abdelhakim M; Althagafi A; Babbi G; Bellazzi R; Bovo S; Carta MG; Casadio R; Coenen PJ; De Paoli F; Floris M; Gajapathy M; Hoehndorf R; Jacobsen JOB; Joseph T; Kamandula A; Katsonis P; Kint C; Lichtarge O; Limongelli I; Lu Y; Magni P; Mamidi TKK; Martelli PL; Mulargia M; Nicora G; Nykamp K; Pejaver V; Peng Y; Pham THC; Podda MS; Rao A; Rizzo E; Saipradeep VG; Savojardo C; Schols P; Shen Y; Sivadasan N; Smedley D; Soru D; Srinivasan R; Sun Y; Sunderam U; Tan W; Tiwari N; Wang X; Wang Y; Williams A; Worthey EA; Yin R; You Y; Zeiberg D; Zucca S; Bakolitsa C; Brenner SE; Fullerton SM; Radivojac P; Rehm HL; O'Donnell-Luria A
    Hum Genomics; 2024 Apr; 18(1):44. PubMed ID: 38685113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a.
    Krimpenfort P; Ijpenberg A; Song JY; van der Valk M; Nawijn M; Zevenhoven J; Berns A
    Nature; 2007 Aug; 448(7156):943-6. PubMed ID: 17713536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Classifying variants of CDKN2A using computational and laboratory studies.
    Miller PJ; Duraisamy S; Newell JA; Chan PA; Tie MM; Rogers AE; Ankuda CK; von Walstrom GM; Bond JP; Greenblatt MS
    Hum Mutat; 2011 Aug; 32(8):900-11. PubMed ID: 21462282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations.
    Potrony M; Puig-Butille JA; Aguilera P; Badenas C; Tell-Marti G; Carrera C; Javier Del Pozo L; Conejo-Mir J; Malvehy J; Puig S
    JAMA Dermatol; 2016 Apr; 152(4):405-12. PubMed ID: 26650189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.
    Cani AK; Hovelson DH; Demirci H; Johnson MW; Tomlins SA; Rao RC
    Oncotarget; 2017 Jan; 8(5):7989-7998. PubMed ID: 28002793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of CDKN2A (p16INK4A/p14ARF) Over-Expression on Proliferation and Migration of Human Melanoma A375 Cells.
    Bai M; Yu NZ; Long F; Feng C; Wang XJ
    Cell Physiol Biochem; 2016; 40(6):1367-1376. PubMed ID: 27997910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families.
    Taylor NJ; Handorf EA; Mitra N; Avril MF; Azizi E; Bergman W; Bianchi-Scarrà G; Bishop DT; Bressac-de Paillerets B; Calista D; Cannon-Albright LA; Cuellar F; Cust AE; Demenais F; Elder DE; Friedman E; Gerdes AM; Ghiorzo P; Goldstein AM; Grazziotin TC; Hansson J; Hayward NK; Hocevar M; Höiom V; Holland EA; Ingvar C; Landi MT; Landman G; Larre-Borges A; Leachman SA; Mann GJ; Nagore E; Olsson H; Palmer J; Perić B; Pjanova D; Puig S; Schmid H; van der Stoep N; Tucker MA; Wadt KAW; Whitaker L; Yang XR; Newton Bishop JA; Gruis NA; Kanetsky PA;
    J Invest Dermatol; 2016 May; 136(5):1066-1069. PubMed ID: 26827760
    [No Abstract]   [Full Text] [Related]  

  • 39. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk.
    Campa D; Pastore M; Gentiluomo M; Talar-Wojnarowska R; Kupcinskas J; Malecka-Panas E; Neoptolemos JP; Niesen W; Vodicka P; Delle Fave G; Bueno-de-Mesquita HB; Gazouli M; Pacetti P; Di Leo M; Ito H; Klüter H; Soucek P; Corbo V; Yamao K; Hosono S; Kaaks R; Vashist Y; Gioffreda D; Strobel O; Shimizu Y; Dijk F; Andriulli A; Ivanauskas A; Bugert P; Tavano F; Vodickova L; Zambon CF; Lovecek M; Landi S; Key TJ; Boggi U; Pezzilli R; Jamroziak K; Mohelnikova-Duchonova B; Mambrini A; Bambi F; Busch O; Pazienza V; Valente R; Theodoropoulos GE; Hackert T; Capurso G; Cavestro GM; Pasquali C; Basso D; Sperti C; Matsuo K; Büchler M; Khaw KT; Izbicki J; Costello E; Katzke V; Michalski C; Stepien A; Rizzato C; Canzian F
    Oncotarget; 2016 Aug; 7(35):57011-57020. PubMed ID: 27486979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing predictions of the impact of variants on splicing in CAGI5.
    Mount SM; Avsec Ž; Carmel L; Casadio R; Çelik MH; Chen K; Cheng J; Cohen NE; Fairbrother WG; Fenesh T; Gagneur J; Gotea V; Holzer T; Lin CF; Martelli PL; Naito T; Nguyen TYD; Savojardo C; Unger R; Wang R; Yang Y; Zhao H
    Hum Mutat; 2019 Sep; 40(9):1215-1224. PubMed ID: 31301154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.